ReviewMaterials today. Bio2026
Carbohydrate polymer-based biomaterials for light-triggered Photo-Immunotherapy: Design strategies, immune mechanisms, and translational outlook.
Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in biomaterials have highlighted the immense potential of carbohydrate polymers (CHPs) as biocompatible, multifunctional platforms for cancer therapy. Indeed, the structural diversity, tunable chemistry, and inherent biological affinity of these polymers enable the precise design of systems for immune modulation. Moreover, light- and laser-driven strategies have emerged as powerful tools for achieving spatiotemporal control over therapeutic activation. Therefore, integrating CHPs with photothermal or photodynamic nanocomponents enables these hybrid systems to induce localized tumor ablation, trigger immunogenic cell death, and remodel the tumor immune microenvironment. These synergistic phototherapy-immunotherapy platforms eradicate primary tumors while promoting systemic antitumor immunity and immune memory formation. Therefore, this review aims to summarize recent advances in CHP-based biomaterials for light-mediated immune activation, focusing on mechanisms, design strategies, and therapeutic outcomes. Furthermore, challenges in tumor-specific targeting, deep-tissue light penetration, and clinical translation are critically discussed. Finally, future perspectives are proposed for the development of next-generation, smart, light-responsive carbohydrate nanomedicines to enable precision cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.